Sirolimus use and cancer incidence among US kidney transplant recipients

American Journal of Transplantation

Volumn 15, Issue 1, 2015, Pages 129-136

  Yanik, E L ^a   Gustafson, S K ^b   Kasiske, B L ^b,c   Israni, A K ^b,c   Snyder, J J ^b,c   Hess, G P ^d,e   Engels, E A ^a   Segev, D L ^b,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Symphony Health Solutions   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK ASSESSMENT; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MIDDLE AGED; NEOPLASMS; PROGNOSIS; REGISTER; UNITED STATES;

ADULT; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; REGISTRIES; RISK ASSESSMENT; SIROLIMUS; UNITED STATES;

EID: 84919651709     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12969     Document Type: Article

References (30)

1. Engels EA, Pfeiffer RM, Fraumeni JF Jr., et al. Spectrum of cancer risk among US solid organ transplat recipients. J Am Med Assoc 2011; 306: 1891-1901.
2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370: 59-67.
3. Douros J, Suffness M., New antitumor substances of natural origin. Cancer Treat Rev 1981; 8: 63-87.
4. Eng CP, Sehgal SN, Vezina C., Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984; 37: 1231-1237.
5. Faivre S, Kroemer G, Raymond E., Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688.
6. Bjornsti MA, Houghton PJ., The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
7. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151-6161.
8. Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z., Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 2003; 38: 25-32.
9. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST., Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716-5722.
10. Halloran PF., Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
11. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR., Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-1156.
12. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317-1323.
13. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339.
14. Gu Y-H, Du J-X, Ma M-L., Sirolimus and, non-melanoma skin cancer prevention after kidney transplantation: A meta-analysis. Asian Pac J Cancer Prev 2012; 13: 4335-4339.
15. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-310.
16. Mathew T, Kreis H, Friend P., Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446-449.
17. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD., Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889.
18. Leppke S, Leighton T, Zaun D, et al. Scientific Registry of Transplant Recipients: Collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev (Orlando) 2013; 27: 50-56.
19. Kasiske BL, McBride MA, Cornell DL, et al. Report of a consensus conference on transplant program quality and surveillance. Am J Transplant 2012; 12: 1988-1996.
20. Azim H, Azim HA Jr, Escudier B., Targeting mTOR in cancer: Renal cell is just a beginning. Target Oncol 2010; 5: 269-280.
21. Zhou L, Huang Y, Li J, Wang Z., The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-261.
22. Darwish OM, Kapur P, Youssef RF, et al. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 2013; 81: 581-586.
23. Kim HS, Kim GY, Lim SJ, Kim YW., Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma. Pathobiology 2012; 79: 84-93.
24. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA., Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
25. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
26. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26: 361-367.
27. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
28. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
29. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589.
30. Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C, deVere White RW., The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. Am J Transplant 2008; 8: 2668-2673.